Oncomine Tumor Mutation Burden TMB Test
Comprehensive Cancer Genetic Analysis for Personalized Treatment
The Oncomine Tumor Mutation Burden TMB test represents a revolutionary advancement in cancer diagnostics, providing clinicians with critical information about a tumor’s genetic landscape. This sophisticated next-generation sequencing analysis measures the total number of mutations present in cancer cells, offering valuable insights that can guide personalized treatment strategies and predict response to cutting-edge immunotherapies.
What is Tumor Mutation Burden Testing?
Tumor Mutation Burden (TMB) refers to the total number of mutations found in the DNA of cancer cells. The Oncomine TMB test utilizes advanced next-generation sequencing technology to comprehensively analyze tumor tissue samples, quantifying the mutation load that can influence how cancer responds to various treatments, particularly immunotherapies.
How the Test Works
The test examines paraffin-embedded tumor tissue blocks using sophisticated genomic sequencing methods to identify and count somatic mutations across hundreds of cancer-related genes. This comprehensive approach provides a quantitative measure of mutation burden that correlates with neoantigen formation and immune system recognition of cancer cells.
What the Oncomine TMB Test Measures
- Total Mutation Count: Quantifies the number of somatic mutations per megabase of DNA
- Mutation Spectrum: Identifies specific types of genetic alterations including single nucleotide variants and small insertions/deletions
- Neoantigen Potential: Assesses the likelihood of mutated proteins being recognized by the immune system
- Immunotherapy Response Prediction: Provides biomarkers for immune checkpoint inhibitor efficacy
Who Should Consider Oncomine TMB Testing?
Clinical Indications
This advanced genetic test is particularly valuable for patients with:
- Advanced solid tumors being considered for immunotherapy
- Cancers with unclear treatment response patterns
- Cases where standard treatment options have been exhausted
- Tumors with high microsatellite instability (MSI-H)
- Patients seeking personalized cancer treatment approaches
Symptoms and Conditions
Patients experiencing cancer progression or those diagnosed with advanced malignancies may benefit from TMB testing to explore immunotherapy options and understand their cancer’s genetic characteristics.
Benefits of Oncomine TMB Testing
Personalized Treatment Guidance
- Immunotherapy Prediction: High TMB levels often correlate with better response to immune checkpoint inhibitors
- Treatment Selection: Helps oncologists choose between immunotherapy, chemotherapy, or targeted therapies
- Clinical Trial Eligibility: May qualify patients for novel immunotherapy clinical trials
- Comprehensive Genetic Profile: Provides detailed insights into tumor biology beyond standard genetic markers
Clinical Advantages
- Evidence-Based Decisions: Supports treatment choices with robust genetic data
- Time Efficiency: Results available within 2-3 weeks for timely treatment planning
- Minimal Sample Requirement: Utilizes standard paraffin-embedded tissue blocks
- Comprehensive Analysis: Examines hundreds of cancer-related genes simultaneously
Understanding Your Test Results
Interpreting TMB Levels
Your results will provide a quantitative TMB score measured in mutations per megabase:
- High TMB: Typically indicates increased likelihood of response to immunotherapy and may suggest eligibility for immune checkpoint inhibitors
- Intermediate TMB: May require additional clinical considerations and discussion with your oncology team
- Low TMB: Suggests alternative treatment approaches may be more appropriate
Clinical Implications
Your healthcare provider will interpret the TMB results in the context of your specific cancer type, stage, and overall health status. High TMB has been associated with improved outcomes in various cancers when treated with immunotherapy, though individual responses may vary.
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | Oncomine Tumor Mutation Burden TMB |
| Regular Price | $1400 USD |
| Discount Price | $1050 USD |
| Turnaround Time | 2-3 weeks |
| Sample Type | Tumor tissue (paraffin-embedded blocks) |
| Testing Method | Next-Generation Sequencing (NGS) |
Pre-Test Instructions and Requirements
The Oncomine Tumor Mutation Burden TMB test requires a physician’s prescription for ordering. Please note that prescriptions are not applicable for surgical cases, pregnancy-related testing, or individuals planning international travel. Your healthcare provider will coordinate sample collection from existing tumor tissue blocks or arrange for new biopsy procedures if needed.
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified laboratories ensures consistent, high-quality testing standards nationwide.
Take the Next Step in Your Cancer Care Journey
Understanding your tumor’s genetic characteristics through Oncomine TMB testing can provide valuable insights for your treatment planning. With advanced next-generation sequencing technology and comprehensive analysis, this test offers critical information that may influence your therapeutic options and clinical outcomes.
Ready to learn more about your cancer’s genetic profile? Contact our genetic specialists today to discuss whether Oncomine TMB testing is appropriate for your situation. Call us at +1(267) 388-9828 or schedule your consultation to explore how this advanced genetic analysis can contribute to your personalized cancer treatment strategy.
Our team of oncology genetic experts is available to answer your questions and guide you through the testing process. Take control of your cancer care with comprehensive genetic insights from the Oncomine Tumor Mutation Burden TMB test.
